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Cigarette smoking is a risk factor for respiratory disorders, cardiovascular diseases and even decrements in muscle
function. Electronic cigarette use (vaping) is considered a healthier alternative to cigarette smoking and may help in
smoking cessation. However, the effects of vaping are not clear yet and particularly the long-term effects of vaping are
largely unknown. Some reports suggest that vaping maybe as harmful for e.g. respiratory function, as cigarette smok-
ing. In this narrative review the effects of vaping and cigarette smoking on respiratory, cardiovascular and muscle
function are compared. Overall, vaping has been found to cause similar effects as smoking on lung function and car-
diovascular function. Future studies are needed to clarify the severity of smoking- and vaping-induced decrements on
muscle function.
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Introduction
Cigarette packages contain warning labels like ‘Smoking kills’
and ‘Smoking clogs the arteries and causes heart attacks and
stroke’. These labels illustrate the tragic truth that smoking is a
major risk factor for the development of cancer, cardiovascular
diseases and respiratory disorders. It causes more than 7 million
deaths per year globally [1] and in 2016, 77,900 deaths in the
United Kingdom (UK) were directly or indirectly attributable to
smoking [2]. Yet, these labels do not appear enough of a deterrent
as about 7.2 million of the UK population are smokers [3]. These
disastrous effects of smoking develop unperceivably slowly and
only later in life the detrimental health issues become evident [4],
a phenomenon referred to as ‘the smoking time-bomb’. To make
matters worse, ‘The beneficial cognitive effects of nicotine have
implications for initiation of smoking and maintenance of tobacco
dependence’ [5].
Any means to administer nicotine, but without the concomitant
inhalation of the more than 4,000 toxic substances in cigarette
smoke, such as acrolein, carbon monoxide, acetaldehyde and cya-
nide, would thus be preferable to cigarette smoking. E-cigarettes
containing nicotine are considered to do this. The success of e-
cigarettes in reducing smoking is reflected by the fact that about
54.1% of the current 3.6 million adult e-cigarette users in the UK
are ex-smokers [6].
There is, however, concern that e-cigarettes may singularly sti-
mulate uptake of smoking, particularly in youth, and have an acute
effect on cardiorespiratory health, even in the absence of smoking
[7,8]. Additionally, there are potential risks with vaping during pre-
gnancy and lactation on the development of the child in the womb
and health of the newborn baby [9-11]. Indeed, vapours from e-
cigarettes contain, besides nicotine and the respiratory irritant
propylene glycol, toxic substances also seen in cigarette smoke,
such as acrolein, acetaldehyde, formaldehyde, and reactive oxygen
species. As seen in animal studies, these toxic substances may well
cause oxidative stress and negative effects on cardiovascular and
respiratory function after vaping [7], casting doubt on the idea that
e-cigarettes are a suitable ‘healthy’ alternative to normal cigarettes.
Yet, there are only basic regulations for the composition of e-ciga-
rette liquids (as described in https://www.gov.uk/guidance/e-ciga-
rettes-regulations-for-consumer-products).
The potential health risk of e-cigarettes led the Forum of
International Respiratory Societies to release a position statement
that concluded: ‘As a precaution, electronic nicotinic delivery
devices should be restricted or banned until more information
about their safety is available’ [8]. There is, thus an unmet need to
know the effects of vaping on cardio-respiratory function in
humans, and how this is related to the daily vaping volume and/or
for how long one has been vaping. Therefore, the aim of this nar-
rative review is to compare the effects of vaping and cigarette
smoking on cardiovascular, respiratory and muscle function.
Vaping and smoking cessation 
Since 1963 cigarette companies have been working to invent a
new smoking system such as electronic nicotine delivery systems
(ENDS) that heats, instead of burns, tobacco to reduce harm, and
presents as a socially acceptable alternative to smoking [12,13].
The credit of inventing the e-cigarette as an alternative to smoking
goes to Hon Lik, a Chinese pharmacist and inventor, whose heavy-
smoking father died from lung cancer [14,15]. Many companies
worldwide have adopted this technology and started marketing e-
cigarettes as an harmless and safe alternative to cigarette smoking
[16]. The focus of this review is therefore on e-cigarettes rather
than heated tobacco products (HTPs) like e.g. iQOS.
Most smokers are aware of the harmful effects of cigarette
smoking. Since the introduction of e-cigarettes in 2003, many
smokers have turned to electronic cigarettes as they are thought to
be less harmful, instead of nicotine replacement therapy (NRT) to
help them quit smoking [17-22]. In 2019, 7.1% of the adult popu-
lation of Great Britain used e-cigarettes [6] and in the European
Union (EU), the use of e-cigarettes increased from 7.2% in 2012 to
11.6% in 2014 [23]. The potential of e-cigarettes or vaping to faci-
litate smoking cessation is illustrated by the 80% decrease in the
use of normal cigarettes after 6 months of vaping [24], and other
studies showing an up to 50% decrease in smoked cigarettes 24
months after taking up vaping [25, 26]. In addition, smoking ces-
sation was reported to be as high as 8.7% 52 weeks after taking up
vaping [26]. In the UK, a recent trial for smoking cessation showed
that using e-cigarette accompanied by behavioural support, such as
face-to-face support, was more effective than NRT [27]. This is a
strong evidence that vaping indeed can reduce smoking. 
Nicotine replacement therapies expose users to low doses of
nicotine [7 to 14 mg/24-hour patch or 2 to 4 mg per piece of gum)
and have been approved as medicinal products by the United
States (US) Food and Drug Administration (FDA) [28]. E-cigaret-
tes are not approved by the FDA and can be bought over the coun-
ter or online also in Europe [28]. The liquid in e-cigarettes have
widely different nicotine concentrations, varying from 8 to 24
mg/ml per cartridge, but even doses up to 100 mg/ml are readily
available [28] and pose a real risk of nicotine poisoning [29]. There
is, indeed, not enough evidence that vaping is safe and has no, or
minor, negative health effects. On the contrary, a study using onli-
ne forums reported 326 negative health-related effects of vaping,
including effects on the respiratory, circulatory, sensory, digestive
and neurological systems [30].
The dangers of nicotine in e-cigarettes
An e-cigarette is composed of a rechargeable lithium battery,
vaporizing chamber and a cartridge that contains the vaping liquid
that consists, among other substances, of nicotine, glycerol, propyle-
ne glycol, glycerine, and tobacco flavouring [31,32], although some
vaping liquids may be free of nicotine. Nicotine is easily absorbed
by the mucus membrane, skin, gastrointestinal tract and respiratory
airways [33] and acts as a neurotransmitter that in turn stimulates the
release of dopamine, which contributes to the feeling of pleasure and
satisfaction as part of the reward pathway [34]. It is this effect of
nicotine that makes smoking so addictive [35]. As mentioned above,
the dose of nicotine in e-cigarettes can be very high; typically, a 5-
mL bottle of e-cigarette refill solution consists of 20 mg/ml nicotine
(that is 100 mg/bottle) [36]. The life threatening dose of nicotine is
around 30 to 40 mg in adults and 10 mg in children [36]. This high
dose combined with unlimited vaping poses a potential health risk as
it has been shown that acute contact to high concentrations of inha-
led nicotine, or even skin contact e.g. after spills of nicotine-contai-
ning solutions, may cause nausea, vomiting or dizziness [33,37].
Such risks are even higher in vaping than in smoking, where such
poisonous nicotine levels rarely occur [38]. In fact, many successful
and unsuccessful suicide attempts through intravenous and oral
intake of the nicotine solution intended for e-cigarette cartridges
have been reported [39-41]. 
Chemical components of e-cigarettes  
Besides nicotine there are other chemicals in the vaping liq-
uids, where propylene glycol constitutes 90% of the e-cigarette liq-
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uid [42]. While propylene glycol is often used to produce the
smoke in special events like rock concerts and is considered harm-
less, prolonged and repeated exposure to propylene glycol vapour
has been reported to cause cough, irritations of the eyes and lungs
[43], and to increase the risk of acquiring asthma [44]. Vaping liq-
uid also contains 1% diethylene glycol, a known carcinogen [31,
45], when non-pharmaceutical grade propylene glycol is used [46].
While many of the flavours in e-liquids are safe when ingested and
widely used in the food industry, the potential dangers of inhaling
flavours are not yet fully investigated, but there are indications
they may have a negative effect on lung health. For example,
diacetyl is used in butter and safe when ingested, but when heated
and inhaled it might cause bronchiolitis [47]. In addition, some
studies have shown that e-cigarettes release aromatic, particularly
the carcinogenic component, polycyclic hydrocarbons, that have a
pathogenic effect on human lung cells [48], and contain esters,
aldehydes, acids or saccharides that are cariogenic [49]. In addition
to these compounds, there are many more carcinogenic compounds
in e-cigarette liquids [45, 50], particularly trace metals (i.e., cadmi-
um, arsenic, chromium, nickel, and lead), and tobacco-specific N-
nitrosamines, and all these substances can in some cases reach con-
centrations even higher than in cigarette smoke [51]. Perhaps most
surprising, given that smoking is a primary risk factor for pul-
monary diseases, is that the most common used e-cigarette refill
liquids are classified as respiratory irritants, allergens, inducers of
asthmatic symptoms or potentially causing breathing difficulties if
inhaled [52]. 
There is as yet no strong evidence that passive exposure to
vaping has adverse effects on health. However, the detrimental
effects of passive smoking and the observation that nicotine
released into the environment does not only affect those who
inhale it, but may also affect non-smokers and non-vapers via nico-
tine left on surfaces e.g. furniture, carpets and clothes [53], strong-
ly hints to the dangers of passive exposure to the e-cigarette
aerosols. 
Effects of vaping and smoking on respiratory
function
Cigarette smoke irritates the lining of the bronchial tubes cau-
sing them to swell and produce mucus to remove smoke particles
[54]. Emphysema may develop when smoke particles irritate the
alveolar walls and inflammation stimulates the release of protea-
ses, enzymes that lead to the destruction of elastic fibres and col-
lagen, which subsequently culminate in the destruction of the
alveolar walls [54, 55]. Over time, this can lead to a decreased ela-
stic recoil of the lung, chronic bronchitis and narrowing of the
bronchial tubes that increases the resistance, and hence, cost of
breathing [54, 56]. Ultimately, this progressive decrease in lung
function can develop into COPD [57] that is diagnosed in 6.6% of
the US population, of which 75% are smokers [58].
In contrast to smoking, the effects of vaping on human health
and respiratory function are poorly investigated [59], but it has
been shown that vaping for just 5 min increased peripheral airway
resistance [60]. This is, however, not unequivocal, as another study
found no acute effects of active vaping on lung function [61].
Whatever the cause of the discrepancy, it has been suggested that
the increased peripheral airway resistance after 5 min of vaping
[60] is partially caused by nicotine [59]. Indeed, nicotine inhala-
tion (0-64 mg/ml) showed a dose-dependent increase in the
amount of coughing and airway obstruction in non-smokers, which
may be a consequence of the stimulation of afferent nerve endings
in the bronchial mucosa by nicotine, which in turn triggers para-
sympathetic cholinergic pathways leading to bronchoconstriction
[62]. Nicotine is, however, not the whole explanation, as respira-
tory symptoms, and airway inflammation were even found in
vapers who used nicotine-free e-cigarettes [63]. 
Over time, the above effects of vaping may cause acute small-
airway constriction and airway epithelial injury [64] that may be
linked to increased risk of wheezing and respiratory symptoms
similar to those seen in cigarette smokers [65]. McCauley et al.
[66] presented a case study of a 42-year old woman diagnosed with
exogenous lipoid pneumonia due to vaping. She had a history of 7-
months productive cough, fevers and dyspnoea which occurred at
the same time of her use of e-cigarettes. After several laboratory
tests, glycerine, which is a component added to e-cigarette liquid
to produce visible smoke to simulate the cigarette smoking expe-
rience, was found to be the causative agent. The symptoms impro-
ved by vaping cessation [66]. The above example may be conside-
red anecdotal, but in a study of 30 vapers who never smoked, it
was seen that the forced expiratory volume in one second (FEV1)
and forced expiratory volume in one second/forced vital capacity
(FEV1/FVC) were significantly lower than those in controls (non-
vapers and non-smokers) [67], similar to that seen in smokers [68,
69] (Figure 1). 
Figure 1. The effect of vaping on A) forced expiratory volume in one second (FEV1) and B) FEV1:FVC (forced vital capacity). Data are
mean ± SD. Data are from Meo et al. [67], and Sparrow et al. [69]. To make the data between the two studies comparable, in each study
the data were normalised to the control group. *Different from controls at p<0.05.
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In contrast to the above cross-sectional study where vapers and
non-vapers were compared [67], in a 3.5-year prospective study no
significant decrements in spirometry or diffusion capacity were
found in vapers [70]. Perhaps studies with a larger sample size are
needed, as there are studies that have also not seen any significant
effect of smoking on respiratory function [71]. Overall, combined
with the detrimental impact of vaping on the lungs of mice [72] the
data suggest that vaping has a detrimental effect on lung function.
Effects of vaping and cigarette smoking on cardio-
vascular function
Smokers suffer from a reduced exercise capacity that is not
only attributable to a reduction in aerobic capacity, but also in
increased metabolic cost of breathing [73-75]. Smoking increases
blood pressure (BP), heart rate (HR), the risk factor for atheroscle-
rosis [76,77] and has been shown to impair cardiovascular func-
tion, increase vascular resistance, and decrease vasodilation and
hence tissue blood flow [76]. The impaired vasodilation [78] can
even occur after short-term smoking [79]. Such an effect is not
limited to the peripheral vasculature. Indeed, a narrowing of the
coronary arteries, and hence decrease in coronary blood flow and
increase coronary resistance, despite an increase in myocardial
oxygen demand, has been reported as a result of acute cigarette
smoking [80]. The authors suggested that such ongoing effects
with prolonged smoking may well contribute to the adverse cardio-
vascular consequences of cigarette smoking, such as myocardial
infarction and cardiac failure [80]. 
There are not many studies on the effects of vaping on exercise
tolerance or cardiovascular function, but Polosa et al. [70] reported
no significant changes in BP and HR in regular e-cigarette users.
However, results of Polosa et al. [70] should be considered with
caution, because of the small sample size (9 vapers vs 12 cigarette
smokers). A meta-analysis that included 11 studies with a total of
283 participants concluded that vaping does acutely increase
resting HR and diastolic BP [81], similar to the effects of cigarette
smoking, but perhaps less pronounced [82]. These effects combi-
ned with the associated increased myocardial demand for oxygen
and nutrients and vasoconstriction may lead to myocardial ische-
mia [83, 84]. Part, or perhaps even most, of these effects may be
caused by nicotine [85], where nicotine increases the HR and BP
primarily by sympathetic neural stimulation and systemic release
of catecholamines [84]. Nicotine-free vaping does not impair vaso-
dilation, increase BP or HR [85], increase arterial stiffness [86,
87], or cause palpations at rest [63]. The absence of a cardiovascu-
lar stimulus from nicotine-free vaping is significant, as people
using other forms of nicotine delivery (smokers, NRT, dual use
vapers and smokers) all had similar levels of circulating nicotine
compared to nicotine-free vapers [88], though others report higher
levels in smokers than vapers [82]. However, nicotine cannot be
the sole culprit as vaping non-nicotinic aerosols also caused impai-
red femoral artery flow-mediated dilation [89]. Based on the cul-
mination of acute responses, this suggests that a chronic e-cigarette
user has an increased risk of increased arterial stiffness and asso-
ciated adverse cardiovascular outcomes and comparative studies
are required to assess whether the effects of smoking on cardiova-
scular health are more severe than those of vaping. Based on the
acute impact of vaping on resting cardiorespiratory and vascular
function, we expect that vaping will impair endurance exercise
capacity. At this point however, more research is required to deter-
mine whether the impact of vaping on endurance exercise capacity,
both in the short and long term, is significant and less than that
from smoking.
Effects of vaping and cigarette smoking on muscle
function and muscle size
Many studies have described the negative effects of smoking
on skeletal muscle function and morphology, specifically, the thigh
muscles [90]. One aspect is decreased muscle fatigue resistance
[71] associated with reduced muscle oxidative capacity [91] and a
slow twitch to fast twitch fibre type transition [92]. A diminished
oxygen delivery due to the interaction of carbon monoxide (CO)
with haemoglobin may hamper the mitochondria to resynthesize
Adenosine triphosphate (ATP). The ability of the mitochondria to
synthesise ATP can be further aggravated by mitochondrial
dysfunction due to interaction of CO and other substances in ciga-
rette smoke with elements of oxidative phosphorylation, and com-
bined with the other changes already discussed, cause a reduction
in muscle contractile endurance [93]. Furthermore, smoking could
promote skeletal muscle wasting via smoking-induced inflamma-
tion that increases protein breakdown and decreases protein
synthesis [93,94] and results in a reduced maximal force-genera-
ting capacity of the muscles from smokers [95,96]. 
There are as yet no studies on the effects of vaping on muscle
function and/or skeletal muscle size. 
Conclusions
In conclusion, despite vaping being marketed as safer and
healthier smoking alternative and a smoking cessation technique,
vaping has been found to cause similar effects as smoking on lung
function and cardiovascular function. There are, however, no stu-
dies on the effects of vaping on muscle function and size. To assess
whether these effects are less than those seen during smoking,
future studies should seek to systematically compare the differen-
ces in severity in the smoking- and vaping-induced decrements in
humans. 
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